polytherapy

polytherapy

(pŏl′ē-thĕr′ă-pē)
Therapy with two or more drugs used at the same time to treat a condition. The term is used most often to describe treatment of seizure disorders with more than one drug; however, it is also used to describe multidrug therapy in Parkinson's disease, schizophrenia, and other brain diseases.
References in periodicals archive ?
Chilakamarri suspects that new drug therapies and polytherapy are leading to movement effects.
With an FDA approval, you get the confidence that what you're giving the patient has instructions based on clinical experience and has a fully characterized safety profile that guides the physician--something especially in polytherapy environments."
Variable Frequency % Duration of illness < 3 years 78 18.9 [greater than 334 81.1 or equal to] 3 years Antipsychotic yes 116 28.2 polytherapy No 296 71.8 Duration of treatment < 2 years 111 26.9 2-5 year 87 21.1 > 5 years 214 51.9 Type of antipsychotics FGA 250 60.7 SGA 46 11.2 FGA+FGA 96 23.3 FGA+SGA 19 4.6 FGA+FGA+SGA 1 0.2 Route of antipsychotics Oral 368 89.3 Injectable ([dagger]) 44 10.7 Number of admissions None 290 70.4 One 66 16.0 [greater than 56 13.6 or equal to] two EPS Yes 43 10.4 No 369 89.6 Drug adherence Yes 243 59.0 No 169 41.0 Substance use No 250 60.7 Yes 162 39.3 EPS, Extrapyramidal side effects; FGA, first generation antipsychotics; SGA, second generation antipsychotics.
CEO Marco Taglietti stated, "For patients dealing with multiple medical issues and polytherapy, these data demonstrate SCY-078's potential as an alternative to current standards of care, especially when the standard of care is well known to cause clinically meaningful drug-drug interactions.
The reasons for medication non-adherent can include age, perception and duration of disease, polytherapy, psychological factors, safety, tolerability and cost.
Polak, "Virtual clinical trial toward polytherapy safety assessment: combination of physiologically based pharmacokinetic/pharmacodynamic-based modeling and simulation approach with drug-drug interactions involving terfenadine as an example," Journal of Pharmaceutical Sciences, vol.
Moreover, our patients were receiving various antithrombotic therapies, ranging from antiplatelet monotherapy to polytherapy with concurrent heparin.
Children under polytherapy have a higher risk of this adverse event [6].
Subjects undergoing polytherapy tended to have AEs more than those undergoing monotherapy while epilepsy duration, seizure frequency, epilepsy type, epilepsy etiology and syndrome, numbers of AEDs, AEDs duration, type of AEDs, and comorbidity did not show any relation with AEs (Table 3).
Moreover, these patients often use AED polytherapy and other drugs targeting the brain, which may cause pharmacodynamic interactions and further increase the risk of disturbed behavior [28, 115].